Table 1.

Baseline and Follow-Up Characteristics (N = 647)

Age at diagnosis, y	64.3 ± 11.1
Male	436 (67.4)
Anticoagulation use at diagnosis	65 (10.0)
Histopathological diagnosis
PA not performed	20 (3.1)
Clear cell	457 (70.6)
Mixed histology	29 (4.5)
Non–clear cell	114 (17.6)
PA performed, but results unknown	27 (4.2)
Tumor grade
Fuhrman grade 1	84 (13.0)
Fuhrman grade 2	254 (39.3)
Fuhrman grade 3	95 (14.7)
Fuhrman grade 4	37 (5.7)
Unknown	177 (27.4)
Stage at diagnosis
Local disease	457 (70.6)
Regional lymph node metastases	18 (2.8)
Distant metastases	172 (26.6)
Performance status (Karnofsky score)
<80%	96 (14.8)
≥80%	451 (69.7)
unknown	100 (15.4)
Anticancer treatment started at diagnosis
(Partial) nephrectomy	395 (61.1)
Radiofrequency ablation	98 (15.1)
Systemic therapy	118 (18.2)
No treatment	29 (4.5)
Total follow-up, mo	24.0 (7.0-24.0)
Status at the end of follow-up
Alive	378 (58.4)
Died	132 (20.4)
Lost to follow-up	137 (21.2)

Values are mean ± SD, n (%), or median (IQR).

PA = pathological analysis.